Stroke:活动性恶性肿瘤患者脑出血后血肿周围水肿特征

2019-11-20 xing.T MedSci原创

由此可见,发生ICH的活动性癌症患者PHE量增加。PHE的生长与血小板减少无关,但与输血有关。30天死亡率与PHE和ICH体积以及血制品输注有关。

活动性恶性肿瘤患者有脑出血(ICH)的风险。近日,心血管疾病领域权威杂志Stroke上发表了一篇研究文章,研究人员旨在归纳无中枢神经系统累及的癌症患者自发性非创伤性ICH后的血肿周围水肿(PHE)和血肿量的特征。

研究人员通过自动检索数据库回顾性地确定发生ICH的活动性恶性患者。对照患者被确定发生ICH且没有活动性癌症的个体。人口统计学和癌症特定数据通过病例审查获得。研究人员使用半自动方法确定血肿和PHE体积。研究人员建立了单变量和多元线性回归模型,以评估哪些变量与血肿和PHE扩张有关。

癌症患者(N=80)和对照组(N=136)的人口统计学特征相似(所有P>0.20),尽管高血压在对照组中更为普遍(P=0.004)。大多数癌症患者最近接受过化疗(n=45,56%)并且发生过恶性肿瘤复发(n=43,54%)。癌症患者同时为血小板减少症患者(血小板中位数为90000 [四分位间距为17500–211500]),并且大多数患者接受了血制品输血(n=41,51%),主要是血小板(n=38,48%)。三十天死亡率为36%(n=29),癌症患者的PHE体积(23.67 vs. 8.61mL;P=1.88×10-9)以及PHE与ICH体积比(2.26 vs. 0.99;P=2.20×10-16)显著增加。在多变量分析中,与癌症患者PHE生长相关的变量是ICH体积(β=1.29 [95%CI为1.58-1.30],P=1.30×10-5)和血小板输注(β=15.67[95%CI为3.61-27.74],P=0.014)。与30天死亡率相关的变量为ICH量(比值比为1.06[95%CI为1.03-1.10],P=6.76×10-5)、PHE量(比值比为1.07 [95%CI为1.04-1.09],P=7.40×10-6)、PHE增长(比值比为1.05[95%CI为1.01-1.10],P=0.01)和血小板输注(比值比为1.48 [95%CI为1.22-1.79],P=0.0001)。

由此可见,发生ICH的活动性癌症患者PHE量增加。PHE的生长与血小板减少无关,但与输血有关。30天死亡率与PHE和ICH体积以及血制品输注有关。 

原始出处:

Aaron M. Gusdon.et al.Perihematomal Edema After Intracerebral Hemorrhage in Patients With Active Malignancy.stroke.2019.https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.027085

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1723981, encodeId=06421e23981a4, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Nov 03 22:08:00 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269165, encodeId=99301269165ca, content=<a href='/topic/show?id=4f99651e3bb' target=_blank style='color:#2F92EE;'>#活动性恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65173, encryptionId=4f99651e3bb, topicName=活动性恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333451, encodeId=719a133345182, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394961, encodeId=7967139496170, content=<a href='/topic/show?id=be548989e09' target=_blank style='color:#2F92EE;'>#血肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89897, encryptionId=be548989e09, topicName=血肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424301, encodeId=2ef6142430128, content=<a href='/topic/show?id=94c182929d0' target=_blank style='color:#2F92EE;'>#肿瘤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82929, encryptionId=94c182929d0, topicName=肿瘤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60943920553, createdName=lanyan20020087, createdTime=Fri Nov 22 11:08:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375580, encodeId=ee383e558079, content=学习了谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Wed Nov 20 20:25:04 CST 2019, time=2019-11-20, status=1, ipAttribution=)]
    2019-11-20 一个字-牛

    学习了谢谢分享学习

    0

相关资讯

J Thromb Haemost:阿哌沙班和达肝素在活动性恶性肿瘤相关的静脉血栓栓塞中的疗效

由此可见,接受VTE治疗的癌症患者口服阿哌沙班与较低的大出血和VTE复发率相关。